Noteworthy ETF Inflows: JQUA, ABT, MCD, ACN
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2025
0mins
Source: NASDAQ.COM
JQUA Stock Performance: JQUA's share price is currently at $60.35, with a 52-week low of $49.2541 and a high of $60.86; the analysis includes comparisons to the 200-day moving average for technical insights.
ETFs Trading Dynamics: ETFs function like stocks but involve trading "units" that can be created or destroyed based on investor demand, impacting the underlying holdings; weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 92.180
Low
136.00
Averages
148.11
High
169.00
Current: 92.180
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Q1 Earnings Beat Expectations, Market Reacts Positively
- AbbVie Revenue Growth: AbbVie reported Q1 revenues of $15 billion, reflecting a year-on-year increase of 12.4% and exceeding analyst expectations by 1.7%, showcasing strong performance from key growth drivers and enhancing the full-year outlook.
- Moderna's Stellar Performance: Moderna achieved Q1 revenues of $389 million, soaring 260% year-on-year and surpassing analyst expectations by 55.8%, marking it as the fastest-growing company among peers, with its stock rising 75.2% since the report, indicating market optimism about its future.
- United Therapeutics Disappoints: United Therapeutics reported revenues of $781.5 million, down 1.6% year-on-year and falling short of analyst expectations, leading to a 3% decline in stock price, highlighting challenges faced in a competitive market.
- Halozyme Exceeds Expectations: Halozyme Therapeutics reported Q1 revenues of $376.7 million, up 42.2% year-on-year and beating analyst expectations by 6.1%, despite a slight miss on full-year EPS guidance, with stock up 16.5%, reflecting market recognition of its technology.
See More
Schwab U.S. Dividend ETF Shows Strong Performance
- CAGR Performance: The Schwab U.S. Dividend ETF has achieved a compound annual growth rate (CAGR) of 13.3% since its inception in 2011, indicating strong performance despite not being available for a full 15 years.
- Dividend Contribution: Approximately 38% of the ETF's total returns come from dividends, highlighting their significance in investment returns; without dividends, an initial $10,000 investment would only be worth about $38,000 today.
- Portfolio Diversity: The ETF currently holds 103 stocks, primarily investing in financially sound U.S. companies that consistently pay dividends, such as Merck, Home Depot, and Coca-Cola, ensuring stability and profitability in its investments.
- Market Comparison: While the Schwab ETF has performed well, an investment of $10,000 in the S&P 500 index fund on October 20, 2011, would have grown to approximately $79,700, illustrating the competitive nature of the market.
See More
The Potential and Returns of Dividend Investing
- Significant Investment Returns: An investment of $10,000 in the Schwab U.S. Dividend Equity ETF 15 years ago would be worth approximately $61,200 today, showcasing the fund's strong performance and appeal.
- Compound Annual Growth Rate: The ETF has achieved a compound annual growth rate of 13.3% since its inception, with an impressive 29% growth rate over the past 12 months, indicating its competitive edge and investment value in the market.
- Importance of Dividends: Dividends accounted for about 38% of total returns since 2011; without them, a $10,000 investment would only be worth $38,000, highlighting the critical role dividends play in investment returns.
- Comparison with S&P 500: While the Schwab ETF has performed well, it still lags behind the Vanguard 500 Index Fund, which would have turned a $10,000 investment into approximately $79,700 during the same period, illustrating the diversity of market options and the importance of selection.
See More
Investment Comparison: Abbott vs. Intuitive Surgical
- Abbott's Diversification Advantage: Abbott operates across four primary segments—medical devices, diagnostics, nutrition, and pharmaceuticals—achieving nearly $44.3 billion in revenue for FY 2025, reflecting a 5.7% year-over-year growth that underscores its stable cash flows and broad customer base across market cycles.
- Intuitive Surgical's Growth Potential: Intuitive Surgical reported approximately $10.1 billion in revenue for FY 2025, marking a significant 20.5% increase, with its robotic surgery platform installed in over 7,500 hospitals globally, indicating strong market demand and high profit margins.
- Financial Health Comparison: Abbott's debt-to-equity ratio stands at about 0.3, indicating a relatively stable financial position, while Intuitive Surgical boasts virtually no debt with a 0.0 ratio and a current ratio of 4.9, showcasing excellent liquidity.
- Risks and Regulatory Challenges: Abbott faces product liability and legal risks, particularly related to its infant formula, while Intuitive Surgical must navigate complex global regulations and cybersecurity threats, factors that could impact the future market performance of both companies.
See More
Baird Initiates Outperform Rating on Abbott Laboratories
- Rating Upgrade: Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target, anticipating stable growth driven by several upcoming catalysts that will enhance the company's market position.
- Growth Expectations: Analyst David Rescott forecasts that Abbott's revenue and earnings will consistently grow by 6%-8% over the coming years, particularly as the company navigates past recent headwinds in respiratory and China diagnostics.
- Acquisition Impact: Despite facing dilution from its $21 billion acquisition of Exact Sciences, Rescott believes that Abbott will see a resurgence in double-digit revenue and earnings growth by 2027, which will bolster investor confidence in the company's long-term prospects.
- Market Performance: Following a more than 25% decline this year, Baird's optimistic outlook could position Abbott as an outperformer among large-cap MedTech peers, potentially attracting increased investor interest in the overall sector.
See More
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
AbbVie Q1 Earnings Beat Expectations, Market Reacts Positively
- AbbVie Revenue Growth: AbbVie reported Q1 revenues of $15 billion, reflecting a year-on-year increase of 12.4% and exceeding analyst expectations by 1.7%, showcasing strong performance from key growth drivers and enhancing the full-year outlook.
- Moderna's Stellar Performance: Moderna achieved Q1 revenues of $389 million, soaring 260% year-on-year and surpassing analyst expectations by 55.8%, marking it as the fastest-growing company among peers, with its stock rising 75.2% since the report, indicating market optimism about its future.
- United Therapeutics Disappoints: United Therapeutics reported revenues of $781.5 million, down 1.6% year-on-year and falling short of analyst expectations, leading to a 3% decline in stock price, highlighting challenges faced in a competitive market.
- Halozyme Exceeds Expectations: Halozyme Therapeutics reported Q1 revenues of $376.7 million, up 42.2% year-on-year and beating analyst expectations by 6.1%, despite a slight miss on full-year EPS guidance, with stock up 16.5%, reflecting market recognition of its technology.
See More
Schwab U.S. Dividend ETF Shows Strong Performance
- CAGR Performance: The Schwab U.S. Dividend ETF has achieved a compound annual growth rate (CAGR) of 13.3% since its inception in 2011, indicating strong performance despite not being available for a full 15 years.
- Dividend Contribution: Approximately 38% of the ETF's total returns come from dividends, highlighting their significance in investment returns; without dividends, an initial $10,000 investment would only be worth about $38,000 today.
- Portfolio Diversity: The ETF currently holds 103 stocks, primarily investing in financially sound U.S. companies that consistently pay dividends, such as Merck, Home Depot, and Coca-Cola, ensuring stability and profitability in its investments.
- Market Comparison: While the Schwab ETF has performed well, an investment of $10,000 in the S&P 500 index fund on October 20, 2011, would have grown to approximately $79,700, illustrating the competitive nature of the market.
See More
The Potential and Returns of Dividend Investing
- Significant Investment Returns: An investment of $10,000 in the Schwab U.S. Dividend Equity ETF 15 years ago would be worth approximately $61,200 today, showcasing the fund's strong performance and appeal.
- Compound Annual Growth Rate: The ETF has achieved a compound annual growth rate of 13.3% since its inception, with an impressive 29% growth rate over the past 12 months, indicating its competitive edge and investment value in the market.
- Importance of Dividends: Dividends accounted for about 38% of total returns since 2011; without them, a $10,000 investment would only be worth $38,000, highlighting the critical role dividends play in investment returns.
- Comparison with S&P 500: While the Schwab ETF has performed well, it still lags behind the Vanguard 500 Index Fund, which would have turned a $10,000 investment into approximately $79,700 during the same period, illustrating the diversity of market options and the importance of selection.
See More
Investment Comparison: Abbott vs. Intuitive Surgical
- Abbott's Diversification Advantage: Abbott operates across four primary segments—medical devices, diagnostics, nutrition, and pharmaceuticals—achieving nearly $44.3 billion in revenue for FY 2025, reflecting a 5.7% year-over-year growth that underscores its stable cash flows and broad customer base across market cycles.
- Intuitive Surgical's Growth Potential: Intuitive Surgical reported approximately $10.1 billion in revenue for FY 2025, marking a significant 20.5% increase, with its robotic surgery platform installed in over 7,500 hospitals globally, indicating strong market demand and high profit margins.
- Financial Health Comparison: Abbott's debt-to-equity ratio stands at about 0.3, indicating a relatively stable financial position, while Intuitive Surgical boasts virtually no debt with a 0.0 ratio and a current ratio of 4.9, showcasing excellent liquidity.
- Risks and Regulatory Challenges: Abbott faces product liability and legal risks, particularly related to its infant formula, while Intuitive Surgical must navigate complex global regulations and cybersecurity threats, factors that could impact the future market performance of both companies.
See More
Baird Initiates Outperform Rating on Abbott Laboratories
- Rating Upgrade: Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target, anticipating stable growth driven by several upcoming catalysts that will enhance the company's market position.
- Growth Expectations: Analyst David Rescott forecasts that Abbott's revenue and earnings will consistently grow by 6%-8% over the coming years, particularly as the company navigates past recent headwinds in respiratory and China diagnostics.
- Acquisition Impact: Despite facing dilution from its $21 billion acquisition of Exact Sciences, Rescott believes that Abbott will see a resurgence in double-digit revenue and earnings growth by 2027, which will bolster investor confidence in the company's long-term prospects.
- Market Performance: Following a more than 25% decline this year, Baird's optimistic outlook could position Abbott as an outperformer among large-cap MedTech peers, potentially attracting increased investor interest in the overall sector.
See More
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
